Pivotal readout

CBT-001 eye drop meets both primary goals in phase 3 pterygium study

Grand Pharmaceutical Group and Cloudbreak Pharma reported that both doses of CBT-001, a reformulated nintedanib emulsion, beat placebo on eye redness after three months and on lesion length after a year (p<0.001) in a 659-patient international trial. Further analyses continue. If approved, it would be the first medicine for pterygium, which is now managed mainly with surgery.

Written by Gosset from public sources. Source types: Press release · SEC/exchange filing. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call